H. Lundbeck B Shares Slide Up to 6.7% After H1 Results Show Growth Deceleration and B-Share Exchange Offer

H. Lundbeck B shares dropped up to 6.7% after H1 revenue grew 16% CER (underlying 13%) and the controlling shareholder launched an A-to-B share exchange offer increasing B-share supply.

H. Lundbeck B shares fell as much as 6.7% to trade near DKK 41.81 on 19 August 2026 after the Danish pharmaceutical company released its first-half results and its controlling shareholder launched a voluntary A-to-B share exchange offer. While total revenue grew 16% at constant exchange rates (CER) to DKK 13,588 million, underlying growth slowed to 13% CER from the stronger +21% CER pace in Q1, prompting a sell-on-the-news reaction. The simultaneous increase in B-share supply added further pressure.

Lundbeck H1 Revenue Climbs 16% CER to DKK 13.6bn as Vyepti Surges; Foundation Launches A-to-B Share Swap

In H1 2026, Lundbeck’s total revenue rose +16% CER (+11% in DKK) to DKK 13,588 million from DKK 12,258 million a year earlier. Adjusting for a planned one-time DKK 470 million inventory build in 27 partner markets in Q1, underlying revenue growth was +13% CER.

Q2 revenue reached DKK 6,463 million, up +12% CER (+7% DKK) from DKK 6,023 million, beating consensus of about DKK 6,229 million. Adjusted EBITDA for Q2 was DKK 1,982 million (margin 30.7%), down slightly from DKK 2,048 million a year earlier but ahead of the DKK 1,945 million consensus. H1 adjusted EBITDA rose +19% CER to DKK 4,765 million. EPS increased 36% to DKK 2.83.

Strategic brands drove performance: Vyepti® revenue jumped +46% CER to DKK 2,865 million; Rexulti® grew +17% CER to DKK 3,297 million; the Abilify LAI franchise rose +7% CER to DKK 1,970 million. The United States contributed DKK 7,227 million (+20% CER). Lundbeck reiterated full-year 2026 guidance of 7–9% revenue growth and 8–14% adjusted EBITDA growth at CER.

On the same day, Lundbeckfond Invest A/S (owned by the Lundbeck Foundation, the controlling shareholder) launched a voluntary 1:1 exchange offer for eligible A-shares into B-shares, open until 16 September 2026. This increases the free-float supply of B-shares.

Lundbeck B Shares Plunge Up to 6.7% on Growth Slowdown and Increased B-Share Supply

H. Lundbeck B (HLUN B / HLUNb on Nasdaq Copenhagen) dropped sharply, with reports of declines around 5–6.7% intraday to levels near DKK 41.60–41.81, versus a previous close of DKK 43.90 and a 52-week high of approximately DKK 47.44–47.78. The move reflected a classic “buy the rumour, sell the news” dynamic after the strong Q1 (when revenue grew +21% CER). Investors focused on the slower underlying H1 pace and sequential normalisation rather than the absolute beat versus consensus. The exchange offer simultaneously expanded B-share supply, creating an additional technical headwind specific to the B class. Broader European markets offered little support amid cautious sentiment linked to Middle East tensions and elevated oil prices.

Brain Specialist with 77% Strategic-Brand Revenue, Dual Shares & ~69% Foundation Stake

H. Lundbeck A/S is a specialist pharmaceutical company focused on brain diseases, with key products including the migraine treatment Vyepti® (eptinezumab), the antipsychotic/antidepressant Rexulti® (brexpiprazole), and the Abilify long-acting injectable franchise. Strategic brands accounted for about 77% of H1 revenue. The company has dual-class shares (A and B); the Lundbeck Foundation, via Lundbeckfond Invest, holds a controlling stake (historically around 69% of capital and higher voting rights). The Foundation’s exchange offer aims to convert A-shares (higher voting power) into more liquid B-shares on a 1:1 basis with no cash component. Lundbeck has been transitioning commercial operations in 27 markets to a partnership model, which included the Q1 inventory build that boosted reported growth.

Investors Watch Exchange Offer Uptake, Vyepti Momentum and Pipeline Progress

Investors will monitor the uptake of the exchange offer (closing 16 September 2026) and any impact on B-share liquidity or potential future delisting discussions around the A-class. Attention will also focus on whether Vyepti® and Rexulti® can sustain momentum to deliver the reiterated full-year guidance, progress on pipeline assets such as bexicaserin (DEEp OCEAN trial enrolment completed), and any further guidance adjustments on gross margin or hedging. Subsequent quarterly updates will clarify the underlying growth trajectory after the partnership-model transition effects fade.